Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD34+ stem cell therapy
- Development stage
- Unknown
- Lead developer
- University Medical Centre Ljubljana
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial, Intracoronary
01
Overview
This autologous CD34+ stem cell therapy, developed by the University Medical Centre Ljubljana, is a cell-based biologic treatment for patients with nonischemic dilated cardiomyopathy (DCM) and chronic heart failure. The therapeutic process involves the mobilization of the patient's own CD34+ hematopoietic stem and progenitor cells from the bone marrow into the peripheral blood using granulocyte colony-stimulating factor (G-CSF/filgrastim). These cells are then collected via apheresis and purified. The resulting cell product is delivered directly to the heart, typically through NOGA-guided transendocardial (intramyocardial) injection or intracoronary infusion. The mechanism of action is primarily attributed to the promotion of neoangiogenesis and the release of paracrine factors that improve myocardial perfusion and viability in failing heart tissue. This therapy has been evaluated in several clinical trials, including the REMEDIUM study, which investigated the efficacy of repetitive dosing.
- Other names
- autologous CD34+ hematopoietic stem cellsCD34+ cell therapyautologous CD34+ hematopoietic stem/progenitor cells
Beyond the preview
Go deeper on autologous CD34+ stem cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD34+ stem cell therapy.